NVAX Stock Analysis: Buy, Sell, or Hold?
NVAX - Novavax Inc
$8.09
-0.36 (-4.26%)
▼
5d:
-16.77%
30d:
-20.22%
90d:
+18.45%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
NVAX is down 6.7% this week, but smart money is accumulating calls. Top strike: $10 2026-04-24 with 164 OI. Call ratio: 79% View Scanner →
Strength: 6.3/10
Get Alerted When NVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NVAX is down 16.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NVAX is down 16.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NVAX is currently trading at $8.09, which is considered oversold relative to its 30-day fair value range of $9.11 to $10.47. From a valuation perspective, the stock is trading at a discount (Forward PE: -24.9) compared to its historical average (35.1). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, NVAX is in a strong uptrend. The price is currently testing key support at $8.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.78 (+70.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NVAX is in a strong uptrend. The price is currently testing key support at $8.06. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.78 (+70.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$9.11 -
$10.47
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding NVAX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.3%)
- BULLISH: Trading 70.3% below Wall St target ($13.78)
- WARNING: Recommendation downgraded due to -16.8% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$9.11 -
$10.47
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$8.07
Resistance Level
$10.94
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-24.90
Wall Street Target
$13.78
(+70.3%)
Revenue Growth (YoY)
66.6%
Earnings Growth (YoY)
-38.1%
Profit Margin
39.2%
PE vs Historical
-24.9 vs 35.1
CHEAP
Share & Embed Analysis
Last updated: March 31, 2026 3:44 AM ET
Data refreshes hourly during market hours. Next update: 4:44 AM
Data refreshes hourly during market hours. Next update: 4:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 58 HOLD |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
15 analysts |
$669 | 67 BUY |
Advanced NVAX Option Strategies
Professional options setups generated by AI based on today's NVAX price and gamma walls.
